In a concerted effort to capitalize on the red-hot global opportunity for neuromodulation therapy, used to treat patients with chronic pain and other debilitating conditions, Action Potential Venture Capital (APVC) Ltd., a new $50 million strategic venture capital fund from pharmaceutical giant GlaxoSmithKline PLC (GSK), has chosen as its first investment neuromodulation device company SetPoint Medical Corp. of Valencia, CA, which will receive $5 million from the APVC fund.
The investment is unique in that it brings a major pharmaceutical market player into the neuromodulation device field, and it...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?